San Antonio BCa Symposium confirmation
Great News for Our Team: MultiplexDX at SABCS 2025
Every year, San Antonio becomes the center of the oncology world during the San Antonio Breast Cancer Symposium (SABCS) - the largest and most prestigious global conference dedicated to breast cancer. With more than 10,000 top experts in attendance, SABCS is where the future of oncology takes shape.
We have been regular participants, and last year we had the honor of presenting the results of our research and clinical validation of our diagnostic test. But this year marks a truly exceptional milestone for us.
For the first time in our history, MultiplexDX will have its own booth at SABCS. In a 20 m² exhibition space, we will showcase our research, scientific results, and our diagnostic test, which is already being used in limited clinical practice. Even more exciting, we will stand alongside global leaders such as AstraZeneca, Novartis, Roche,Pfizer, Gilead, Daiichi Sankyo, Merck, Bayer, Guardant Health, Myriad Genetics,Tempus, Illumina, Bio-Rad, Paige AI, and many more.
Earning this place was far from easy. The SABCS committee is highly selective, granting space only to those with tangible scientific results, patents, clinical data, and impactful research. Forus, it is more than just recognition. It is an opportunity to proudly represent Slovakia’s science, talent, and perseverance on one of the biggest global stages in oncology.
About MultiplexDX
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.
Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter
